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Abstract
Current evidences suggest that expression of Ki67, cyclooxygenase (COX), aromatase,
adipokines, prostaglandins, free radicals, β-catenin and α-SMA might be involved in breast
cancer pathogenesis. The main objective of this study was to compare expression/localiza-
tion of these potential compounds in breast cancer tissues with tissues collected adjacent to
the tumor using immunohistochemistry and correlated with clinical pathology. The breast
cancer specimens were collected from 30 women aged between 49 and 89 years who
underwent breast surgery following cancer diagnosis. Expression levels of molecules by dif-
ferent stainings were graded as a score on a scale based upon staining intensity and pro-
portion of positive cells/area or individually. AdipoR1, adiponectin, Ob-R, leptin, COX-1,
COX-2, aromatase, PGF2α, F2-isoprostanes and α-SMA were localised on higher levels in
the breast tissues adjacent to the tumor compared to tumor specimens when considering
either score or staining area whereas COX-2 and AdipoR2 were found to be higher consid-
ering staining intensity and Ki67 on score level in the tumor tissue. There was no significant
difference observed on β-catenin either on score nor on staining area and intensity between
tissues adjacent to the tumor and tumor tissues. A positive correlation was found between
COX-1 and COX-2 in the tumor tissues. In conclusion, these suggest that Ki67, COXs, aro-
matase, prostaglandin, free radicals, adipokines, β-catenin and α-SMA are involved in
breast cancer. These further focus the need of examination of tissues adjacent to tumor,
tumor itself and compare them with normal or benign breast tissues for a better understand-
ing of breast cancer pathology and future evaluation of therapeutic benefit.
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Introduction
Breast cancer is a clinically heterogeneous disease [1] linking a variety of complex contribu-
tors and interactions that are closely interrelated to indigenous inflammation. There are
growing number of evidences suggest that expression of Ki67, cyclooxygenase (COX), aro-
matase, prostaglandins, free radicals, adipokines, β-catenin and α-SMA might be involved in
breast cancer pathogenesis [2–5]. Tumor-associated macrophages harvest a variety of
inflammatory mediators that have a vital role in integrity of cellular matrix and proliferation,
angiogenesis, invasion and eventual metastasis [6]. It had also been identified that COX-2 is
overexpressed in 40% of the invasive human breast cancer, and is related to cell proliferation,
metastasis, survival and elevated endogenous prostaglandin levels [7]. Inflammatory media-
tors such as COX-2 and adipocytokines are also known to involve in the carcinogenesis in a
mouse model of mammary cancer and human breast cancer [8,9]. Epidemiological studies
suggest that non-steroidal anti-inflammatory drugs (NSAIDs) have some protective effects
to human cancer and transgenic COX-2 overexpressed mice induce mammary tumor forma-
tion. Further, canonical Wnt/β-catenin signaling seems to play an important role in meta-
static breast cancer [10,11].
According to the American Institute for Cancer Research, Washington D.C., advanced obe-
sity is a potential cause of postmenopausal breast cancer which is related to inflammation [12].
Involvement of inflammation, in addition to adipokines and obesity in breast cancer seem to
be a convincing theory, since a huge interest has been developed in the current years in study-
ing the function of leptin and adiponectin in mammary tumor growth [13–17]. Both these
important proteins/hormones are potential candidates in the process of carcinogenesis, specifi-
cally in the obesity-related breast cancer. A significant role is played by the adipose tissue that
consists of a blend of mature adipocytes, macrophages and undifferentiated fibroblasts. There-
fore, an unstable adipose tissue microenvironment could have an immense impact on breast
cancer development [18]. This is probably due to the well-known fact that pro-carcinogenic
effect of leptin and anti-carcinogenic effect of adiponectin could be interrelated to the inflam-
matory response and cell proliferation in the tumor microenvironment [3,15]. Leptin generally
acts through its receptor (Ob-R), which is encoded by the Ob gene and activates JAK/STAT
(Janus kinase/signal transducer) signaling pathway that increases cell migration and invasion
of breast cancer cells. Whereas adiponectin usually initiates cell growth inhibitory effects
through its two receptors (AdipoR1 and AdipoR2) via adenosine monophosphate-activated
protein kinase (AMPK) pathway. In addition, higher aromatase activity is closely associated to
the tumor growth in the breast through estrogen synthesis by the specific stimulation of prosta-
glandin E2 and cAMP signaling [19–23]. Together, breast cancer development is a complex
multi-step endogenous regulatory process that includes appearance of various crucial media-
tors at different progressive stages together with genetic and epigenetic influences of the patient
[21,24–26].
On these vital standpoints described above, Ki67, COXs, eicosanoids, aromatase, adipo-
kines, β-catenin and α-SMA are all potential contributors in cell proliferation and breast can-
cer development. However, no such study has been evaluated these potential mediators
expressed in situ mutually and their coexistence in tumor microenvironment of human
breast cancer. This study describes the direct expression/localization of Ki67, COXs, aroma-
tase, eicosanoids, adipokines and their receptors (Ob-R, AdipoR1 and AdipoR2), β-catenin
and α-SMA in breast cancer specimens using immunohistochemistry and correlated with
pathological parameters.
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Materials and Methods
Tissue collection
Breast tissue samples from 30 women aged between 49 and 89 years who underwent surgery in
2009 were obtained from the tumor bank at the Jean-Perrin Anti-Cancer Center, Clermont-
Ferrand. The breast tissue samples were obtained from the Jean Perrin Biological Centre, Cen-
tre Jean-Perrin, Clermont-Ferrand, France with ethical permission obtained from the French
Ministry of Higher Education and Research. The authorization number is BB-0033-00075.
Each patient was informed about the use of biological tissue samples for research purposes. If
the patient agree on the consent, a non-refusal notice is kept in patient's file. The procedure has
been agreed by the Peoples Protection Committee (Nr. AC-2013-1882).
For each patient, two tissue samples were collected: 1) the mammary tumor and, 2) the tis-
sue adjacent to the tumor. Tissue samples were collected during surgery and stored in liquid
nitrogen until analysis. The clinical pathological characteristics such as menopausal state, body
mass index and tumor histological grade were collected based on pathological reports and
medical records.
Immunofluorescence detection
Tissues were embedded in Optimal Cutting Temperature compound (Tissue-Tek1, Sakura
Finetek USA, Torrance, CA) and cutted in sections of 10μm thick using cryostat (Leica,
CM1950). After fixation by paraformaldehyde 4% slides were blocked with a solution of PBS
5% donkey serum, 5% Fish skin gelatin, 1% Triton and 0.5% Tween20, and stained by indirect
immunofluorescence. First antibodies were diluted in 1% PBS:BSA, 1% Triton, 0.5% Tween20
and incubated overnight at 4°C. The following antibodies rabbit monoclonal anti-COX-2 pre-
diluted (ab21704, Abcam, Cambridge, UK), anti-Ki67 (1:100; AB9260, Millipore, Molsheim,
France), anti-β-catenin (1:100, 9582P, Cell Signaling Technology), anti-α-SM22 (1:1000,
ab14106, Abcam, Cambridge, UK) were used in the study and are commercially available.
Anti-8-iso-prostaglandin-F2α (8-iso-PGF2α) and anti-15-keto-13,14-dihydro-prostaglandin-
F2α (15-keto-dihydro-PGF2α) used at 1:1000 were raised in rabbit as previously described
[27,28]. Ethical permission was obtained to raise these antibodies in 1996 with permission
from the Ethical Committee, Faculty of Medicine, Uppsala University, Uppsala, Sweden. The
authorization number is C 298/96. Antibodies for leptin (1:40, AF398, R&D Systems, Lille,
France), anti-Ob-R (1:40, AF389, R&D Systems, Lille, France), anti-AdipoR1 and anti-Adi-
poR2 (1:100, ab77611 and ab77612, Abcam, Cambridge, UK) and anti-aromatase (1:100,
SAB2500110, Sigma, Saint-Louis, USA) were produced in goat. Anti-adiponectin (1:200,
ab22554, Abcam, Cambridge, UK) and anti-COX-1 (1:250, ab695, Abcam, Cambridge, UK)
were mouse antibodies and are commercially available. For negative controls, sections were
incubated without primary antibodies. Tissues were then washed and incubated for one hour
at room temperature with 4’,6 diamidino-2-phenylindole (DAPI, 0.5μg/ml) and the second
antibody: AlexaFluor 488-conjugated donkey anti-rabbit, or 555-conjugated donkey anti-goat
or goat anti-mouse IgG (Invitrogen, Paisley, UK) diluted at 1:1000 in PBS BSA 1% were used
in the experiments. After that, sections were mounted in a drop of Mowiol (Calbiochem,
France). Part of these stainings were done together with COX-2 and leptine, Ki67 and Adipo
R1, β-catenin and AdipoR2, COX-1 and α-SM22 and COX-2 and aromatase. Confocal laser-
scanning microscopy was performed with the LeicaTCS SP5 MP confocal and multiphoton
microscope system (Leica Inc., Heidelberg, Germany) in collaboration with ICCF (http://www.
iccf.fr/). Digital images were processed using Adobe Photoshop CS5.1 and compiled using
Adobe Illustrator CS5.1 (Adobe Systems Inc., San Jose, CA). The intensity of the stainings were
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visually appreciated such as-, +/-, +, +/++, ++, ++/+++, +++ and converted to number (- = 0,
+/- or + or +/++ = 1 and ++ or ++/+++ or +++ = 2). The average number of stained positive
cells (Ki67) or positive area (all other stainings) per microscopic field (magnification 20X) was
quantified using the particle analyzer from ImageJ software (National Institutes of Health,
Bethesda, MD, USA). Images were subjected to the threshold function and then the number of
particles in the image or the area was counted. Particles less than 10 pixels were excluded from
the study.
Interpretation of immunofluorescence staining
Expression levels of the molecules by different stainings were graded as a score on a scale of 0
to 2 based on staining intensity and proportion of positive cells or positive area. The staining
was scored as 0 if no cells were reactive, 1 if staining was weakly positive with<2/3 of positive
cells or strongly positive with<1/3 positive cells and 2 if staining was weakly positive with>2/
3 positive cells or strongly positive with>1/3 positive cells. The final scores were classified as
negative (score 0) or positive (1 or 2). For Ki67 staining, data were expressed as the ratio Ki67+
nucleus number on total nucleus number. For β-catenin staining, data were expressed as the
ratio number of tissues samples stained either in nucleus, or in cytoplasm, or both on total
number of tissues samples analyzed.
Statistical analysis
The data were expressed as the mean ± SEM. Differences between tissues adjacent to the tumor
and tumor tissues groups were assessed using Student paired T test. Pearson test was used to
check correlation between two biomarkers. Spearman test, test H, H Kruskall and Wallis were
used for β-catenin expression and correlation study with clinical parameters. Similarly, Pearson
test, test H Kruskall and Wallis, Mann and Whitney U test were used for Ki67, COX-2 expres-
sion and correlation study with clinical parameters. Overall survival of patients and COX-2
was estimated by Chi2 test.
Results
Clinical characteristics of the patients
Clinical characteristics of the patients are shown in Table 1. The mean age of the patients was
65 years (range, 49–89). Menopausal state of the patients was as follows: 4 patients were of pre-
menopausal state (13%), 24 patients were of postmenopausal (80%) state and it is unknown for
2 subjects. The mean BMI of the patients was 26.2 kg/m2 (range 20.8–37.6 kg/m2). A total of 13
patients were overweighted (BMI>25 kg/m2, according to the World Health Organisation)
and 15 patients were of normal weight (BMI 18.5–24.9 kg/m2). 27 (90%) patients were of ductal
carcinoma, 1 patient was of lobular carcinoma and 2 patients of dual character. Positive lymph
node involvement were in 13 cases (43.3%). Histologic grades of the tumor were as follows:
grade 1 in 5 cases (16.7%); grade 1–2 in 2 cases (6.7%), grade 2 in 13 cases (43.3%) and grade 3
in 10 cases (33.3%). Estrogen receptor (ER) positive was in 29 cases (97%) and progesterone
receptor (PR) positive was in 25 cases (83%). No overexpression of HER-2 was seen in 28 cases
(93%).
Immunofluorescence staining data
Significant higher level of cell proliferation marker Ki67 was found in the nucleus of tumor tis-
sue (6.90±4.74) than in the tissue adjacent to the tumor (1.18±1.19) (p = 0.0001) (Table 2).
Similarly we observed more β-catenin staining in the nucleus of the tumor tissue than in the
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nucleus of the tissue adjacent to the tumor (2/3 cells with cytoplasmic staining in the healthy
tissue adjacent to the tumor and 1/3 cells with cytoplasmic staining in the tumor tissue). Fig 1
shows adjacent breast tissue to tumor (left panel) and breast tumor tissues (right panel) labeled
Table 1. Clinical characteristics of patients (n = 30).
Variables Number (range, %)
Age (year) 65 (49–89)
BMI (kg/m2) 26.2 (20.8–37.6)
18.5 to 25 15 (50)
25 to 30 8 (26.7)
30 to 35 3 (10)
35 to 40 2 (6.7)
Unknown 2 (6.7)
Menopausal state Premenauposal 4 (13.3)
Postmenauposal 24 (80)
Unknown 2 (6.7)
Type Ductal invasive 27 (90)
Lobular invasive 1 (3.3)
Dual invasive 2 (6.7)
Lymph node involvement Negative 17 (56.7)
Positive 13 (43.3)
Histologic grade Grade 1 5 (16.7)
Grade 1–2 2 (6.7)
Grade 2 13 (43.3)
Grade 3 10 (33.3)
ER expression Negative 1 (3.3)
Positive 29 (96.7)
PR expression Negative 5 (16.7)
Positive 25 (83.3)
HER-2 expression No overexpression 28 (93.3)
Overexpression 2 (6.7)
BMI = Body Mass Index; ER = Estrogen Receptor; PR = Progesterone Receptor; HER = Human
epidermal growth factor receptor
doi:10.1371/journal.pone.0138443.t001
Table 2. Comparison of proliferation markers (Ki67 and β-Catenin) in breast tissues adjacent to the tumor and tumor tissues of breast cancer
patients based on immunohistochemistry staining.
Biomarkers Breast tumor tissue (n = 30) Adjacent breast tissue to tumor (n = 30) Paired T test p<0.05
Ratio (Ki67+ nucleus / total nucleus) 6.90±4.74 1.18±1.19 0.0001
β-Catenin C C + N N C C + N N 0.02
n = 10 n = 18 n = 2 n = 19 n = 9 n = 2
C (% area*) N (% area) C (% area) N (% area)
69 31 51 49
C: cytoplasma; N = nucleus; n = number of samples
* % area stained.
doi:10.1371/journal.pone.0138443.t002
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by indirect immunofluorescence for A) β-catenin and B) Ki67 with DAPI as nuclear
counterstain.
Table 3 shows a comparison between tissues adjacent to the tumor and tumor tissues col-
lected from breast cancer patients on different parameters based on the score calculated from
the percent of total stained area and intensity of immunostaining. A representative figure
Fig 1. β-Catenin and Ki67 immunostaining in adjacent breast tissue to tumor or breast tumor tissue. Adjacent breast tissue to tumor or breast tumor
tissue labeled by indirect immunofluorescence for A/ β-catenin and B/ Ki67 (green) with DAPI as nuclear counterstain (blue).
doi:10.1371/journal.pone.0138443.g001
Inflammation and Cell Proliferation Markers in Breast Cancer
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shows adjacent breast tissue to tumor (left panel) and breast tumor tissues (right panel) labeled
by indirect immunofluorescence for A) Adiponectin and B) AdipoR1 and AdipoR2 with DAPI
as nuclear counterstain (Fig 2). AdipoR1 was significantly lower in the tumor tissue than the
tissues adjacent to the tumor (p = 0.027). Ob-R, the leptin receptor levels were significantly
lower in the tumor tissue than the tissues adjacent to the tumor (p = 0.01). In addition, both
leptin and adiponectin levels were also significantly lower in the tumor tissue compared to the
tissues adjacent to the tumor (leptin, p = 0.027; adiponectin, p = 0.0023). Ratio between adipo-
nectin and leptin levels were indifferent comparing either of the tissues (0.89±0.96 in the
tumor tissue and 1.03±095 in the tissue adjacent to the tumor, p = ns). Fig 3 shows adjacent
breast tissue to tumor (left panel) and breast tumor tissues (right panel) labeled by indirect
immunofluorescence for A) Leptin and B) Leptin receptor Ob-R with DAPI as nuclear
counterstain.
COX-1, being the constitutive enzyme that keeps the homeostasis and prostaglandin bio-
synthesis was not different in the tissues adjacent to the tumor compared to the tumor tissue.
COX-2, F2-isoprostanes and PGF2α were lower in the tumor tissue than tissues adjacent to the
tumor (COX-2, p = 0.016; 8-iso-PGF2α, p = 0.026; PGF2α, p = 0.05). Fig 4 shows adjacent breast
tissue to tumor (left panel) and breast tumor tissues (right panel) labeled by indirect immuno-
fluorescence for A) COX-1 and B) COX-2 with DAPI as nuclear counterstain. α-SMA was
higher in the tissues adjacent to the tumor than tumor tissues (p = 0.027) and aromatase was
indifferent comparing either of the tissues.
Tables 4 and 5 show a comparison between tissues adjacent to the tumor and tumor tissues
collected from breast cancer patients on different parameters based on the percent of total
stained area and intensity of immunostaining, respectively. AdipoR1 was significantly higher
in the tissues adjacent to the tumor (p = 0.0031) compared to the tumor tissues when consider-
ing percent of area stained whereas indifferent levels were found when compared on the stain-
ing intensity levels. AdipoR2 showed an opposite spectrum than AdipoR1 on intensity levels
than percent of total stained area. Adiponectin values were significantly higher (p = 0.022) and
Table 3. Comparison of adipokines and their receptors (AdipoR1, AdipoR2 and Ob-R), COXs, F2-isoprostanes, prostaglandin F2α, α-SMA and aro-
matase in breast tissues adjacent to the tumor and tumor tissues of breast cancer patients based on a score calculated from the staining intensity
and percent of area immunostained tissues.
Breast tumor tissues Adjacent breast tissues to
tumor
Biomarkers n Score n Score Paired T test p<0.05
AdipoR1 27 0.93±0.27 25 1.24±0.36 0.027
AdipoR2 30 0.83±0.28 29 0.83±0.34 ns
Adiponectin 29 0.90±0.19 25 1.15±0.46 0.0023
Ob-R 30 1.00±0.00 28 1.21±1.34 0.01
Leptin 30 1.07±0.12 27 1.26±0.38 0.027
COX-1 28 1.18±0.29 26 1.38±0.47 ns
COX-2 27 0.70±0.42 24 0.95±0.09 0.016
F2-isoprostanes 29 0.48±0.50 25 0.64±0.51 0.026
PGF2α 29 0.55±0.49 26 0.73±0.39 0.05
α-SMA 30 0.79±0.55 27 1.19±0.42 0.027
Aromatase 26 1.04±0.22 26 0.96±0.07 ns
Results are the mean ± SEM; ns = not signiﬁcant; Adipo R1/R2 = adiponectin receptor; Ob-R = leptin receptor; COX = cyclooxygenase; PGF2α =
prostaglandin F2α; α-SMA = α-Smooth Muscle Actin
doi:10.1371/journal.pone.0138443.t003
Inflammation and Cell Proliferation Markers in Breast Cancer
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Fig 2. Adiponectin and Adiponectin receptors immunostaining in adjacent breast tissue to tumor or breast tumor tissue. Adjacent breast tissue to
tumor or breast tumor tissue labeled by indirect immunofluorescence for A/ Adiponectin, and B/ Adiponectin receptor 1 and C/ Adiponectin receptor 2 (red)
with DAPI as nuclear counterstain (blue).
doi:10.1371/journal.pone.0138443.g002
Fig 3. Leptin and Leptin receptor immunostaining in adjacent breast tissue to tumor or breast tumor tissue. Adjacent breast tissue to tumor or breast
tumor tissue labeled by indirect immunofluorescence for A/ Leptin and B/ Leptin receptor Ob-R (red) with DAPI as nuclear counterstain (blue).
doi:10.1371/journal.pone.0138443.g003
Inflammation and Cell Proliferation Markers in Breast Cancer
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leptin was lower (p = 0.00005) on intensity levels in the tissues adjacent to the tumor compared
to the tumor tissues but both adiponectin and leptin values were higher (adiponectin,
p = 0.0009; leptin, p = 0.0000001) in the tissues adjacent to the tumor compared to the tumor
tissues on the percent of stained area. Ob-R (p = 0.0000001) values was higher on the percent
Fig 4. COX-1 and COX-2 immunostaining in adjacent breast tissue to tumor or breast tumor tissue. Adjacent breast tissue to tumor or breast tumor
tissue labeled by indirect immunofluorescence for A/ COX-1 (red) and B/ COX-2 (green) with DAPI as nuclear counterstain (blue).
doi:10.1371/journal.pone.0138443.g004
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of area stained in the tissues adjacent to the tumor than tumor tissues whereas no such differ-
ence was observed when counting staining intensity.
COX-1 values were lower in the tumor tissues than tissues adjacent to the tumor (p = 0.0015)
on the percent of stained area. There was less COX-2 in the tumor than in the tissues adjacent to
the tumor (with a large SEM) (p = 0.0096) considering the percent area stained as seen for the
score above. However when considering the intensity, COX-2 values are significantly lower
(p = 0.009) for tissues adjacent to the tumor compared to tumor tissues. F2-isoprostanes and
PGF2αmetabolite levels were higher both on the percent of area stained (F2-isoprostanes,
Table 4. Comparison of adipokines and their receptors (AdipoR1, AdipoR2 and Ob-R), COXs, aromatase, F2-isoprostanes, prostaglandin F2α, α-
SMA and aromatase in breast tissues adjacent to the tumor and tumor tissues of breast cancer patients on the basis of percent of staining area.
Breast tumor tissues Adjacent breast tissues to
tumor
Biomarkers n % area stained N % area stained Paired T test p<0.05
AdipoR1 27 11.71±10.67 25 24.97±13.87 0.0031
AdipoR2 30 7.15±6.34 29 8.97±7.57 ns
Adiponectin 29 4.07±3.64 25 10.47±7.85 0.0009
Ob-R 30 9.02±6.51 28 23.20±11.37 <0.0000001
Leptin 30 9.90±7.46 27 23.74±19.45 <0.0000001
COX-1 28 17.00±10.62 26 35.23±20.35 0.0015
COX-2 27 1.09±1.13 24 3.41±3.87 0.0096
F2-isoprostanes 29 1.21±1.42 25 6.42±6.73 0.0048
PGF2α 29 2.19±2.89 26 6.68±5.16 0.012
α-SMA 30 12.40±15.24 27 23.81±16.79 ns
Aromatase 26 8.22±8.97 26 15.94±9.93 0.0067
Results are the mean ± SEM; ns: not signiﬁcant. AU = Arbitrary Unit; Adipo R1/R2 = adiponectin receptor; Ob-R = leptin receptor; COX = cyclooxygenase;
PGF2α = prostaglandin F2α; α-SMA = α-Smooth Muscle Actin
doi:10.1371/journal.pone.0138443.t004
Table 5. Comparison of adipokines and their receptors (AdipoR1, AdipoR2 and Ob-R), COXs, F2-isoprostanes and prostaglandin F2α, α-SMA and
aromatase in the breast tissues adjacent to the tumor and tumor tissues of breast cancer patients on the basis of staining intensity.
Breast Tumor tissues Adjacent breast Tissue to
tumor
Biomarkers n Intensity (AU) n Intensity (AU) Paired T test p<0.05
AdipoR1 27 1.30±0.63 25 1.37±0.47 ns
AdipoR2 30 1.27±0.64 29 0.86±0.36 0.022
Adiponectin 29 1.14±0.42 25 1.50±0.55 0.0023
Ob-R 30 1.57±0.49 28 1.46±0.50 ns
Leptin 30 1.80±0.32 27 1.33±0.44 0.00005
COX-1 28 1.86±0.24 26 1.69±0.43 ns
COX-2 27 0.63±0.51 24 0.33±0.44 0.009
F2-isoprostanes 29 0.59±0.61 25 0.76±0.61 0.025
PGF2α 29 0.72±0.65 26 1.04±1.59 0.037
α-SMA 30 1.17±0.86 27 1.67±0.49 0.02
Aromatase 26 1.50±0.58 26 1.32±0.48 ns
Results are the mean ± SEM; ns: not signiﬁcant. AU = Arbitrary Unit; Adipo R1/R2 = adiponectin receptor; Ob-R = leptin receptor; COX = cyclooxygenase;
PGF2α = prostaglandin F2α; α-SMA = α-Smooth Muscle Actin
doi:10.1371/journal.pone.0138443.t005
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p = 0.0048; PGF2α, p = 0.012) and intensity levels in the tissues adjacent to the tumor than tumor
tissues (F2-isoprostanes, p = 0.025; PGF2α, p = 0.037). Fig 5 shows adjacent breast tissue to tumor
(left panel) and breast tumor tissues (right panel) labeled by indirect immunofluorescence for A)
F2-isoprostanes and B) PGF2α with DAPI as nuclear counterstain.
Fig 5. F2-isoprostane and PGF2α immunostaning in adjacent breast tissue to tumor or breast tumor tissue. Adjacent breast tissue to tumor or breast
tumor tissue labeled by indirect immunofluorescence for A/ F2-isoprostane and B/ PGF2α (green) with DAPI as nuclear counterstain (blue).
doi:10.1371/journal.pone.0138443.g005
Inflammation and Cell Proliferation Markers in Breast Cancer
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Using multivariate survival analysis considering the whole population, the overall survival is
found to be 87.7% at 5 years. When considering two groups selected by COX-2 median value,
we observe no significant difference for overall survival for tissue adjacent to the tumor,
whereas the underexpression of COX-2 is associated with lower but no significant overall sur-
vival with a follow up of 4.7 years (p = 0.38) for tumor tissue. Thus with regard to the small
number of patients, this study cannot conclude on the survival rate.
α-SMA levels were higher (p = 0.02) in the tissues adjacent to the tumor than the tumor tis-
sues on intensity level but not on staining area. Aromatase (p = 0.0067) values was higher on
the percent of area stained in the tissues adjacent to the tumor than tumor tissues whereas no
such difference was observed when counting staining intensity. Fig 6 shows adjacent breast tis-
sue to tumor (left panel) and breast tumor tissues (right panel) labeled by indirect immunoflu-
orescence for A) Aromatase and B) α-SMA with DAPI as nuclear counterstain.
Since some of the women in this study are postmenopausal we have analysed the aromatase
score values selecting the two groups of post- and premenopausal women. For postmenopausal
the aromatase score is: breast tumor tissues (n = 22), 1.05 +/- 0.49; and adjacent breast tissue to
tumor (n = 22), 1.00 +/- 0.00; When performed paired T test no significance is found
(p = 0.79). For premenopausal women the aromatase score is: breast tumor tissues (n = 3), 1.00
+/- 0.00; and adjacent breast tissue to tumor (n = 4), 0.75 +/- 0.43; When performed Mann and
Whitney test no significance has been obtained (p = 0.50). Thus, the menopausal status does
not seem to confound the analysis.
Correlations between cyclooxygenases and adipokines, aromatase and
prostaglandins
Correlations between COX-1 and AdipoR1, AdipoR2, adiponectin, leptin, aromatase, PGF2α
metabolite were shown in Table 6. No correlation was found between these parameters. Corre-
lations between COX-2 and AdipoR1, AdipoR2, adiponectin, leptin, aromatase, PGF2αmetab-
olite are shown in Table 7. However, a positive correlation was found between COX-1 and
COX-2 in the tumor tissues.
Correlation between β-catenin, Ki67, Her2/neu and clinical pathology
Correlation between β-catenin and age is significant regardless the type of tissue (tumor or
healthy: globally, p = 0.0005). All other correlations are not significant considering the tumor
volume (= tumor diameter), the degree of differentiation (histologic grade), the lymph node
involvement and the tumor-node-met staging. As expected, correlation with Ki67 and histo-
logic grade (or SBR) is found to be significant (p = 0.0045). Correlations with other clinical
pathology parameters are not significant considering the age, the tumor volume (= tumor
diameter), the lymph node involvement and the tumor-node-met staging. Correlation between
Her2/neu and clinical pathology parameters is not possible to perform due to only two tumors
overexpressed this parameter (Table 1).
Discussions
In this study we have observed a higher level of cell proliferation marker, Ki67 in the tumor tis-
sue which is in accordance with earlier studies [2, 29] and also correlates with histologic grade.
Ki67 is a nuclear protein that is encoded with MK 167 gene which is associated with and pre-
requisite for cell proliferation. This is a prominent marker to elucidate the growth of a certain
cell population. Ki67 protein is present in all active phases of the cell cycle process, and is usu-
ally absent from resting cells. The fraction of Ki67-positive tumor cells is generally associated
with the clinical outcome of cancer, such as breast and prostate cancer [29,30]. In a coherent
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way, the nuclear or cytoplasmic staining of the β-catenin, a protein of the Wnt pathway, also
shows a proliferation more important in the tumor cells than in the cells of the tissue adjacent
to the tumor. Indeed, the nuclear localization of β-catenin shows an activation of the Wnt path-
way, a major way of cell proliferation.
Fig 6. Aromatase and α-SMA immunostaning in adjacent breast tissue to tumor or breast tumor tissue. Adjacent breast tissue to tumor or breast
tumor tissue labeled by indirect immunofluorescence for A/ Aromatase (red) and B/ α-SMA (green) with DAPI as nuclear counterstain (blue).
doi:10.1371/journal.pone.0138443.g006
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This study demonstrate that adiponectin, AdipoR1, leptin, Ob-R, COX-1, COX-2, aroma-
tase, F2-isoprostanes, PGF2αmetabolite and α-SMA are localised on higher levels in the breast
tissues adjacent to the tumor compared to tumor specimens either on a score calculated from
both the staining area and intensity or individually on the staining area or intensity of staining.
More specifically, when evaluating score alone AdipoR1, adiponectin, Ob-R, leptin, COX-2,
F2-isoprostanes, PGF2α and α-SMA were also higher in the tissues adjacent to the tumor com-
pared to the tumor tissues. Further, Ki67 was found in higher levels in the tumor tissues. The
results also show that AdipoR1, adiponectin, Ob-R, leptin, aromatase, COX-1, COX-2, F2-iso-
prostanes and PGF2α were higher in the tissues adjacent to the tumor compared to the tumor
tissues based on percent of staining area whereas AdipoR2, leptin and COX-2 were higher in
the tumor tissues compared to the breast tissues adjacent to the tumor based on the percent of
staining intensity. Breast tissues adjacent to the tumor showed higher levels of adiponectin, F2-
isoprostanes, PGF2α and α-SMA compared to the tumor tissues based on the percent of stain-
ing intensity. Collectively, these results suggest that expression of these potential pathophysio-
logical mediators (adipocytokines and their receptors, COXs, aromatase, Ki67, and α-SMA, F2-
Table 6. Correlation between staining score values of COX-1 and adipokines and their receptors, aromatase and PGF2α in adjacent breast tissue
and tumor tissues as performed by Pearson test.
COX-1
Biomarkers Breast tumor tissues (Mean±SEM: 1.18±0.29, n = 28) Adjacent breast tissue to tumor (Mean±SEM: 1.38±0.47,
n = 26)
Mean±SEM n r ddl p Mean±SEM n r ddl p
AdipoR1 0.93±0.27 27 -0.152 23 0.470 1.24±0.36 25 -0.258 19 0.260
AdipoR2 0.83±0.28 30 0.217 26 0.270 0.83±0.34 29 0.062 23 0.770
Adiponectin 0.90±0.19 29 -0.135 25 0.510 1.15±0.46 25 0.048 22 0.820
Leptin 1.07±0.12 30 -0.900 26 0.650 1.26±0.38 27 -0.098 22 0.650
Aromatase 1.04±0.22 26 0.000 22 1.000 0.96±0.07 26 0.167 23 0.430
PGF2α 0.55±0.49 29 0.780 25 0.700 0.73±0.39 26 0.065 22 0.760
COX-1 = cyclooxygenase-1; Adipo R1/R2 = adiponectin receptor; PGF2α = prostaglandin F2α
doi:10.1371/journal.pone.0138443.t006
Table 7. Correlation between staining score values of COX-2 and adipokines and their receptors, aromatase, COX-1 and PGF2α in healthy and
tumor tissues as performed by Pearson test.
COX-2
Biomarkers Breast tumor tissues (Mean±SEM: 0.70±0.42, n = 27) Adjacent breast tissue to tumor (Mean±SEM: 0.53±0.50,
n = 24)
Mean±SEM N r ddl p Mean±SEM N r ddl p
AdipoR1 0.93±0.27 27 0.033 25 0.860 1.24±0.36 25 -0.185 23 0.380
AdipoR2 0.83±0.28 30 0.000 28 1.000 0.83±0.34 29 0.128 27 0.510
Adiponectin 0.90±0.19 29 0.174 27 0.370 1.15±0.46 25 -0.051 24 0.800
Leptin 1.07±0.12 30 -0.055 28 0.770 1.26±0.38 27 -0.239 25 0.230
Aromatase 1.04±0.22 26 -0.106 24 0.610 0.96±0.07 26 0.143 26 0.470
COX-1 1.18±0.29 28 -0.389 26 0.039 1.38±0.47 26 -0.013 24 0.950
PGF2α 0.55±0.49 29 -0.133 27 0.500 0.73±0.39 26 0.217 24 0.290
COX = cyclooxygenase; Adipo R1/R2 = adiponectin receptor; PGF2α = prostaglandin F2α
doi:10.1371/journal.pone.0138443.t007
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isoprostanes and PGF2α) are confined either in the adjacent tissues to the breast tumor or in
the tumor itself. This disparate identification of the compounds through different detections
procedures might indicate a differential availability of these compounds in the microenviron-
ment of both in the tumor and the tissues adjacent to the tumor. This manifestation may possi-
bly have an influence on the appearance and disappearance of systemic levels of these
compounds and also on biological effects at various stages of the disease in patients. These dis-
tinctive appearances of these compounds in the cells most possibly have further impact on the
growth of the tumor and subsequently intensifying their stimulus to the neighboring tissues.
AdipoR1, adiponectin, Ob-R and leptin were higher on score and area of staining in the tis-
sues adjacent to the tumor than the tumor tissue. However, higher intensity of staining was
seen for leptin in the tumor than in the tissues adjacent to the tumor as shown in the earlier
studies [9,31,32]. When determining intensity alone adiponectin, PGF2α, F2-isoprostanes levels
were higher in the tissues adjacent to the tumor than the tumor tissue whereas AdipoR2, leptin,
and COX-2 levels were higher in the tumor tissues. Higher levels of α-SMA were also seen in
the tissues adjacent to the tumor compared to the tumor both on the score and intensity of
staining.
COX-2, COX-mediated product PGF2α and F2-isoprostanes, a free radical mediated product
of arachidonic acid on score values and aromatase, COX-1, COX-2, PGF2α, F2-isoprostanes on
percent of staining area levels were also higher in the tissues adjacent to the tumor than the
tumor tissue. Similar higher levels on intensity were also found for PGF2α and F2-isoprostanes.
Some eicosanoids specifically promote further development and growth of breast tumor indi-
rectly by inducing aromatase, particularly in the estrogen positive breast cancer [33], and
nearly all cases presented here (29 out of 30) belong to this group. Earlier it has shown that
higher levels of COX-2 in the tumor tissues than in normal mammary gland tissue [5,33,34] as
it is seen in the current study when we consider intensity of staining. These differential appear-
ances perhaps are due to the fundamental molecular alterations occurring that are reflected by
histologically characterized so called normal appearing adjacent tissues. The question then
arises how “normal healthy” the tissues are adjacent to the breast tumor. This issue on the
selection of tissues for scientific judgement has earlier been highlighted in other studies
[35,36]. Tissues adjacent to the primary breast cancer tissues could be not of same character
when using normal or benign breast tissue as a comparison which we have not determined in
our study. However, other study has indicated that adjacent breast specimens from triple-nega-
tive breast cancer, which were all positive for CD44+CD49fCD13372+ stem cell staining, also
exhibited high tumorigenic signature patterns [36]. Similarly, it has also been described that
immunohistochemical expression of COX-2, IL-10 and Ki67 was higher in tumor stromal
areas than tumor cell areas [37]. These observations certainly highlight that adjacent normal
tissue to the tumor tissues have already acquired a number of transcriptional changes compara-
ble to the tumor tissues. Further, these studies together emphasis that microenvironment sur-
rounding tumor epithelium is of vital importance to scrutiny and plays a crucial role in breast
cancer progression [18]. An appropriate normal breast tissue as a baseline comparison with
adjacent tumor tissue and the tumor tissue itself will essentially give a more precise indication
of the disease dissemination to the neighboring cells. A positive correlation was found between
COX-1 and COX-2 in the tumor tissues in this study which is expected since both these
enzymes are closely-related subtypes. Both COXs are well connected to inflammatory environ-
ments and are responsible for subsequent prostaglandin formation [38,39]. Together, this
study presents the presence of Ki67, AdipoR1, AdipoR2, adiponectin, Ob-R, leptin, aromatase,
COX-1, COX-2, PGF2α, F2-isoprostanes and α-SMA are localised on higher levels in the breast
tissues adjacent to the tumor or in the tumor itself which may have pathological consequences
in the breast cancer.
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This study has some limitations regarding the small number of patient samples inclusion.
Further, we conducted immunohistochemical analysis only on the breast that undergone sur-
gery in breast cancer diagnosed patients but not compared with healthy breast tissues. Thus,
we had any baseline normal or benign breast tissue sample for comparison with the tumor tis-
sues mainly due to ethical reasons of access of healthy breast tissue samples. In addition, there
remains always a risk of misclassification of the single section with the histopathological pat-
tern of the specimen that may sometime overlook the localisation. However, the sections were
always been carefully collected and the results were cautiously judged by an experienced
pathologist to determine the authenticity and characteristics of the sample. Despite these limi-
tations, our study has several strengths, such as we have evaluated and presented the results in
the cancer microenvironment through immunohiostochemical positive staining cells/area or
intensity of staining individually and also through a careful judgement of the score calculated
from both the intensity and the staining area. In addition, we have determined several potential
variants of parameters in the same samples that are currently regarded as important mediators
and contributors in breast cancer pathology. Further, the majority of the patients were at post-
menopausal stage diagnosed with estrogen and prosgesterone receptor positive and having
ductal carcinoma, those are the important criteria’s that coincide with many of the selected var-
iables and parameters we have studied.
In conclusion, this immunohistochemical study shows that AdipoR1, adiponectin, Ob-R,
leptin, aromatase, COX-1, COX-2, PGF2α, F2-isoprostanes and α-SMA are expressed and local-
ised on higher levels in the breast tissues adjacent to the tumor compared to tumor specimens
when considering either score or staining area whereas AdipoR2, leptin and COX-2 were also
found on staining intensity and Ki67 on score level in the tumor tissue. Further these findings
heighten the need of investigation of adjacent tumor microenvironment together with tumor
and normal or benign breast tissues to understand the multifaceted existence and interactions
of numerous mediators in breast cancer pathology and future evaluation of therapeutic benefit.
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